Group 1 - The company, Stone Four Pharmaceutical Group, announced that it will hold a board meeting on August 28, 2025 [1] - The purpose of the meeting includes approving the publication of the unaudited interim results for the six months ending June 30, 2025, for the company and its subsidiaries [1] - The board will also consider the proposal for the payment of an interim dividend, if any [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 周興揚 香港，二零二五年八月十八日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先 生及曲婉蓉女士，非執行董事劉文軍先生以及獨立非執行董事王亦兵先生、周國偉先生 及姜廣策先生。 董事局會議召開日期 石四藥集團有限公司（「本公司」）宣佈，本公司將於二零二五年八月二十八日舉行董事局會 議，藉以（其中包括）批准刊發本公司及其附屬公司截至二零二五年六月三十日止六個月之未 經審核中期業績公告及考慮派付中期股息（如有）之建議。 承董事局命 執行董事兼公司秘書 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 2005) （於開曼群島註冊成立之有限公司） （股份代號：2005） ...

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Core Viewpoint - The approval of Azilsartan by the National Medical Products Administration of China marks a significant milestone for the company, as it can now be used as an active pharmaceutical ingredient in marketed formulations [1] Company Summary - The company, Stone Four Pharmaceutical Group, has received regulatory approval for Azilsartan, an angiotensin II receptor blocker (ARB) [1] - Azilsartan is primarily used for the treatment of hypertension by blocking the effects of angiotensin II to lower blood pressure [1]

Core Viewpoint - The approval of Azilsartan by the National Medical Products Administration of China marks a significant milestone for the company, allowing it to be used as an active pharmaceutical ingredient in marketed formulations [1] Company Summary - The company, Stone Four Pharmaceutical Group, has received regulatory approval for Azilsartan, which is classified as an angiotensin II receptor blocker (ARB) [1] - Azilsartan is primarily indicated for the treatment of hypertension by blocking the effects of angiotensin II to lower blood pressure [1]

自願公告 產品開發的最新進展 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年八月十四日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的阿齊沙坦已獲中國國家藥品監督管理局批准登記成為在上市製劑使用的原料藥。阿齊 沙坦是一種血管緊張素 II 受體拮抗劑（ARB），通過阻斷血管緊張素 II 的作用而降低血壓，主 要用於治療高血壓。 ...

Core Viewpoint - The announcement highlights that Stone Four Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Amaprine to be registered as an active pharmaceutical ingredient for use in marketed formulations, making it the first company in the country to achieve this [1] Company Summary - Stone Four Pharmaceutical Group's Amaprine is a potassium channel blocker primarily used to improve walking speed in adults with certain types of multiple sclerosis [1]

石四药集团(02005)发布公告，集团的氨吡啶已获中国国家药品监督管理局批准登记成为在上市制剂使 用的原料药，是国内首家获批。氨吡啶是一种钾通道阻滞剂，主要用于改善某些多发性硬化症成年人步 行速度。 ...

智通财经APP讯，石四药集团(02005)发布公告，集团的氨吡啶已获中国国家药品监督管理局批准登记成 为在上市制剂使用的原料药，是国内首家获批。氨吡啶是一种钾通道阻滞剂，主要用于改善某些多发性 硬化症成年人步行速度。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的氨吡啶已獲中國國家藥品監督管理局批准登記成為在上市製劑使用的原料藥，是國內 首家獲批。氨吡啶是一種鉀通道阻滯劑，主要用於改善某些多發性硬化症成年人步行速度。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年八月十三日 ...